メリーランド州における転移性癌の臨床試験
メリーランド州内の拠点で、転移性癌に関する47件の研究が参加者を募集しています。
メリーランド州内の都市
公式研究テキスト（英語）
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
- National Institutes of Health Clinical Center, Bethesda
- 他1件
被験者募集中第2相
全年齢 · 全性別 · 2026/10/02更新 · NCT05564377Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Maryland Oncology, Columbia
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07562152Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Greater Baltimore Medical Center, Baltimore
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07222800Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Maryland Oncology Hematology, P.A., Annapolis
- Maryland Oncology Hematology, P.A., Bethesda
- Maryland Oncology Hematology, P.A., Brandywine
- 他5件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07222566A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- JHU Oncology Central Kit Services, Baltimore
- Johns Hopkins Hospital, Baltimore
- Oncology Investigational Drug Service (IDS), Baltimore
- 他1件
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06989437A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Columbia
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06103864Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
- John Hopkins University, Baltimore
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06915753A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Johns Hopkins Hospital, Baltimore
- James M Stockman Cancer Institute, Frederick
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07218380A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- American Oncology Partners, PA, Bethesda
- James M Stockman Cancer Institute, Frederick
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07174336A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Greater Baltimore Medical Center, Baltimore
- Sinai Hospital Of Baltimore, Baltimore
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07213804Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/16更新 · NCT06606990The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第2相
18歳〜98歳 · 全性別 · 2026/09/16更新 · NCT04927416Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT03907475The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第2相
18歳〜90歳 · 全性別 · 2026/09/09更新 · NCT03841617NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies
- Johns Hopkins, Baltimore
被験者募集中第1相
19歳以上 · 全性別 · 2026/09/08更新 · NCT07563829A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Johns Hopkins Bayview Medical Center, Baltimore
- USO - Maryland Oncology Hematology, Columbia
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06119581Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- The Center for Cancer and Blood Disorders a division of American Oncology Partners, P.A., Bethesda
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06072612T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第2相
18歳〜72歳 · 全性別 · 2026/08/31更新 · NCT02133196Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/24更新 · NCT05687136FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- Johns Hopkins Kimmel Cancer Center, Baltimore
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/20更新 · NCT05614739A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
- Research Site, Baltimore
被験者募集中第2相
18歳〜130歳 · 全性別 · 2026/08/18更新 · NCT06792695FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center, Baltimore
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05919264Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/13更新 · NCT05691517Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/03更新 · NCT05687110Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/31更新 · NCT05691491A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Maryland Oncology Hematology - Primary, Columbia
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/30更新 · NCT04657068Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Baltimore
- Research Site, Baltimore
- Research Site, Silver Spring
被験者募集中第3相
18歳以上 · 女性 · 2026/07/29更新 · NCT07044336REMASTer: REcurrent Brain Metastases After SRS Trial
- University of Maryland, Baltimore
被験者募集中
18歳以上 · 全性別 · 2026/06/18更新 · NCT05124912E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/12更新 · NCT05686226Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
- Advanced Molecular Imaging and Therapy, Glen Burnie
- United Theranostics - Chesapeake, Glen Burnie
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/11更新 · NCT05283330Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Johns Hopkins University, Baltimore
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/03更新 · NCT06040541Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
- University of Maryland, Baltimore
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/02更新 · NCT04617522A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- John Hopkins University, Baltimore
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/05/27更新 · NCT05384626Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- American Oncology Partners, P.A., Bethesda
被験者募集中第3相
18歳以上 · 全性別 · 2026/05/18更新 · NCT06757634Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Johns Hopkins University, Baltimore
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/15更新 · NCT05379985Studying TAK-243 in Patients With Advanced Cancer
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
被験者募集中第1相
18歳以上 · 全性別 · 2026/05/13更新 · NCT06223542Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
- The Center for Cancer and Blood Disorders, Bethesda
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/05/08更新 · NCT06697301A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Johns Hopkins University, Baltimore
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/22更新 · NCT07020221A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- University of Maryland, Baltimore
被験者募集中第3相
18歳以上 · 全性別 · 2026/04/09更新 · NCT06064877Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
- Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore
被験者募集中第2/3相
18歳以上 · 男性 · 2026/04/08更新 · NCT04787744ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。